Synapse - Solid Tumor Oncology Division

Results (1292)

Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients

Meeting Abstract

Italiano, A.; Hong, D. S.; Briggs, A.; Garcia-Foncillas, J.; Lassen, U. N.; Vassal, G.; Kummar, S.; van Tilburg, C. M.; Keating, K.; Reeves, J. A.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Meeting Abstract

Drilon, A.; Paz-Ares, L.; Doebele, R. C.; Farago, A. F.; Liu, S. V.; Chawla, S. P.; Tosi, D.; Blakely, C. M.; Krauss, J. C.; Bazhenova, L.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours

Meeting Abstract

Paik, P. K.; Xiong, W.; Hietala, S. F.; Nyberg, J.; Papasouliotis, O.; Anziano, R.; Berghoff, K.; Johne, A.; Girard, P.; Strotmann, R.
Annals of Oncology (2020)

Fulltext@MSK | Save

Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study

Meeting Abstract

Conley, A. P.; Demetri, G. D.; Doebele, R. C.; Drilon, A.; Paz-Ares, L.; Cassier, P.; Siena, S.; Ahn, M. J.; Buchschacher, G. L. Jr; Seto, T.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer

Meeting Abstract

Gouda, M. A.; Sherman, E. J.; Gilcrease, G. W.; Vaishampayan, U. N.; Parikh, A.; Feun, L.; Kummar, S.; Huang, H.; Zhang, C.; Severson, P.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy

Meeting Abstract

Liu, S. V.; De Braud, F.; Drilon, A.; Doebele, R. C.; Patel, M. R.; Cho, B. C.; Ahn, M. J.; Chiu, C. H.; Farago, A. F.; Goto, K.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies

Meeting Abstract

Ku, G.; Bendell, J. C.; Tolcher, A. W.; Hurvitz, S. A.; Krishnamurthy, A.; El-Khoueiry, A. B.; Patnaik, A.; Shroff, R. T.; Noonan, A.; Hahn, N. M.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer

Meeting Abstract

Strickler, J.; Ng, K.; Cercek, A.; Fountzilas, C.; Sanchez, F.; Hubbard, J.; Wu, C.; Stecher, M.; Walker, L. N.; Bekaii-Saab, T.
Annals of Oncology (2020)

Fulltext@MSK | Save

A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab plus chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009

Meeting Abstract

Rugo, H. S.; Llombart Cussac, A.; André, F.; Robson, M.; Saji, S.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Seok Ahn, J.; Nanda, R.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)

Meeting Abstract

Kaufman, P. A.; Martin, M.; Mayer, I.; Vahdat, L. T.; Pernas Simon, S.; Schmid, P.; McArthur, H. L.; Dent, R.; Rugo, H. S.; Barrios, C.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save